Biotechnology Stock

Durect Cp

We are an emerging specialty pharmaceutical company focused on the development of pharmaceutical products based on our proprietary drug delivery technology platforms. We are developing pharmaceutical systems that will deliver the right drug to the right place in the right amount at the right time to treat chronic or episodic diseases and conditions. By integrating chemistry and engineering ... more

Edwards Lifesciences Corp

Edwards Lifesciences Corporation ("Edwards Lifesciences" or the "Company") is a global provider of products and technologies that are designed to treat advanced cardiovascular disease. Edwards Lifesciences focuses on providing products and technologies to address specific cardiovascular opportunities: heart valve disease; peripheral vascular ... more

Insite Vision, Inc

We are an ophthalmic product development company focused on ophthalmic pharmaceutical products based on our proprietary DuraSite® eyedrop-based drug delivery technology, as well as the development of genetically-based technologies for the diagnosis, prognosis and management of glaucoma. more

Pharma Net Devp

As used in this Form 10-KSB "we", "our", "us" and "SFBC" refer to SFBC International, Inc. and its subsidiaries unless the context requires otherwise. We provide pharmaceutical and biotechnology companies with specialized drug development services primarily in the areas of Phase I and Phase II clinical trials and bioanalytical laboratory services. With the acquisition of New Drug Services Inc. ... more

Delta And Pine Land Co.

Delta and Pine Land Company, a Delaware corporation, and subsidiaries ("D&PL") is primarily engaged in the breeding, production, conditioning and marketing of proprietary varieties of cotton planting seed in the United States and other cotton producing nations. We also breed, produce, condition and market soybean planting seed in the United States. more

Metabasis Therapeutics, Inc

· Advancing the development of our product candidates . We currently have five product candidates in clinical development. These product candidates, in order from the most advanced in clinical trials, are pradefovir, CS-917, MB07803, MB07133 and MB07811 indicated for the treatment of hepatitis B, type 2 diabetes, primary liver ... more

Sangamo Biosciences, Inc

Sangamo BioSciences is developing a new class of human therapeutics. We are a leader in the research, development, and commercialization of DNA-binding proteins for the therapeutic regulation and modification of disease-related genes. Our proprietary technology platform is based on the engineering of a naturally occurring class of proteins referred to as zinc ... more

Sonus Pharmaceuticals, Inc

Sonus Pharmaceuticals is focused on the development of cancer drugs that are designed to provide better efficacy, safety and tolerability, and are easier to use. Our business strategy is as follows: more

Entremed, Inc

EntreMed, Inc. (“EntreMed” or “the Company”) (Nasdaq: ENMD) is a clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells directly and the blood vessels that nourish them. EntreMed is focused on developing drugs that we believe are safe and convenient, and provide the potential for ... more

Allos Therapeutics, Inc

Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with one or more potential strategic partners. The key elements of our business strategy are to: more

Acorda Therapeutics

As of December 31, 2005, we had an accumulated deficit of approximately $208.0 million. We had net losses of $35.5 million and $44.7 million for the years ended December 31, 2005 and December 31, 2004, respectively. We have had operating losses since inception as a result of our significant clinical development, research and development, general and ... more

Curis, Inc

We and our collaborators may not achieve our projected research and development goals in the time frames we announce and expect, which could have an adverse impact on our business and could cause our stock price to decline. more

Senomyx, Inc

We are a leading company focused on using proprietary taste receptor-based assays and screening technologies to discover and develop novel flavors, flavor enhancers and taste modulators, which we refer to as flavor ingredients, for the packaged food and beverage industry. We believe our flavor ingredients will enable packaged food and beverage companies to improve the nutritional profile of ... more

Surmodics, Inc

SurModics, Inc. (referred to as “SurModics,” “the Company,” “we,” “us,” “our” and other like terms) is a leading provider of surface modification and drug delivery technologies to the healthcare industry. Our technologies include, among others, our PhotoLink ® surface modification coatings, our drug ... more

Anadys Pharmaceuticals, Inc

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company committed to the discovery, development and commercialization of small-molecule medicines for the treatment of hepatitis and cancer. Our current clinical development programs include: ANA975, an oral prodrug of the Toll-like receptor-7 (TLR-7) agonist isatoribine, for the treatment of hepatitis C virus ... more